<DOCUMENT>
<TYPE>EX-10.60
<SEQUENCE>6
<FILENAME>d824216dex1060.htm
<DESCRIPTION>EX-10.60
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.60</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.60 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED</B> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CONSENT&#146; AND AMENDMENT AGREEMENT (this &#147;Amendment Agreement&#148;) is made as of June&nbsp;4, 2004 by and among, Titan
Pharmaceuticals, Inc., a corporation having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (&#147;Titan&#148;), and Novartis Pharma AG, a corporation having its principal office at Lichtstrasse 35, CH 4002,
Basel, Switzerland (&#147;NOVARTIS&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Aventis (formerly Hoechst Marion Rousel, Inc. (&#147;HMRI&#148;)) and Titan are parties to that certain License Agreement effective
as of December&nbsp;31, 1996 (the &#147;License Agreement&#148;): and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Titan and Novartis are parties to that certain Sublicense
Agreement effective as of November&nbsp;20, 1997 as. amended, (the &#147;Sublicense Agreement&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Novartis desires to
sublicense its rights and obligations under .the Sublicense Agreement to Vanda Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (&#147;Vanda&#148;), pursuant to a sublicense agreement (the &#145;Vanda Sublicense
Agreement&#148;) and the parties hereto desire to facilitate the execution of the Venda Sublicense Agreement by pleading certain of the tennis of the Sublicense Agreement. Terms not otherwise defined in this Amendment Agreement shall have the
meanings set forth in the Sublicense Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants and agreements hereinafter set
forth and for other good and valuable consideration the receipt of which is hereby acknowledged, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Definitions</U>. The definition of &#147;Field&#148; set forth in Section&nbsp;1.12 of the Sublicense Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Field&#148; shall mean the treatment in humans of psychiatric disorders, including psychotic disorders and analgesia;
provided, however, that for purposes solely of the Vanda Sublicense Agreement warty approved sublicense thereunder, &#147;Field&#148; shall mean the application to all conditions, disorders and &amp;cases in humans&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. For purposes of the Vanda Sublicense Agreement or any approved sublicense thereunder, Section&nbsp;2.2 of the Sublicense Agreement shall be
deleted in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. For purposes of the Vanda Sublicense Agreement or any approved sublicense. thereunder, Section&nbsp;2.3 of
the Sublicense Agreement shalt be deleted in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Grant</U>. Section&nbsp;2.5 of the Sublicense Agreement is modified to
provide that each of Aventis, Titan and Novartis will have **** after notification thereof in accordance with the Sublicense Agreement to inform Vanda of any objection tai the trademark. selections). </P> 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Subsection 3.4(a) of the Sublicense Agreement shall be deleted in its entirety and
replaced by the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 (a)&nbsp;In order to spread royalty payments hereunder, over a. sufficient period of time,
in each of those countries in the TERRITORY where the PATENTS claiming a priority date of May&nbsp;19, 1989 and December&nbsp;29, 1989 in a particular country for which a patent had been granted validly claiming Iloperidone or the manufacture,
formulation or use hereof for use in the FIELD have expired, NOVARTIS&#146; obligations to pay royalties for use of PATENTS in such country shell cease, and NOVARTIS and/or any of its SUBLICENSEES shall pay directly to HMRI a royalty for **** of
**** percent (****%) on NOVARTIS&#146;, its AFFILIATES&#146; and any SUBLICENSEES&#146; annual NET SALES of the PRODUCT in each such country for **** after the expiration of the final remaining PATENT in each such country. After the end of such
****, no further royalties arising from sales of the PRODUCT in such country shall be due to HMRI and NOVARTIS, its AFFILIATES and any SUBLICENSEES shall be entitled to continue to use **** on a fully-paid, irrevocable basis in accordance with
Section&nbsp;10.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Subsection 3.4(b) of the Sublicense Agreement shall be del in its entirety and replaced by the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the event a THIRD PART Y&#146;s generic version of Iloperidene is actively marketed in a process patent country (that is, any country in
which only protection in relation to processes for the manufacture of Iloperidene has been obtained and not protection for Iloperidene as a new chemical entity per se) in the TERRITORY where a PATENT(s) has been granted validly claiming Iloperidene
or the manufacture, formulation or use thereof for use in the FIELD exists, then subject to Sections 3,4(0) and (d)&nbsp;below, the royalty rate that NOVARTIS, shall pay to TITAN on NOVARTIS&#146; or its AFFILLIATE&#146;s or SUBLICENSEE&#146;s
annual NET SALES of PRODUCT in that process patent country shall be **** percent (****%) until such PATENT(s) expires, provided: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="13%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD> 
<TD ALIGN="left" VALIGN="top">**** </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="13%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD> 
<TD ALIGN="left" VALIGN="top">**** Unless otherwise agreed to by the PARTIES, **** </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="6%" VALIGN="top" ALIGN="left">****</TD> 
<TD ALIGN="left" VALIGN="top">C<SMALL>ERTAIN</SMALL> <SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL>
<SMALL>PORTIONS</SMALL>. </TD></TR></TABLE> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">**** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. For purposes of the Venda Sublicense Agreement or any approved sublicense thereunder, Subsection 5.6 of the Sublicense Agreement shall be
deleted in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Exchange-of Information and Confidentiality</U>. The first sentence of Section&nbsp;6.4 of the Sublicense
Agreement is amended by deleting the words &#147;and for ****&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Intellectual Property</U>. The Sublicense Agreement is hereby
amended to include the following provision: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, in the event that the Venda
Sublicense Agreement expires or terminates, in its entirety or with respect to any country, (except as a result of material breach of that agreement by Novartis), then, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD> 
<TD ALIGN="left" VALIGN="top">Novartis shall make certain and take all action necessary so that Venda delivers all inventions-or discoveries or improvements which arise from Venda&#146;s, its Affiliates&#146; and Sublicensees&#146; work relating to
the development and/or manufacture of the Compound and/or Product (the &#147;Venda IP&#148;) to Than or Aventis **** of the termination or expiration of the Venda Sublicense Agreement: and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD> 
<TD ALIGN="left" VALIGN="top">Novartis will make certain that Titan or Aventis has full access, at Titan&#146;s or Aventis&#146; request, to all Venda IP in the possession of Novartis (as the case may be). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the Venda Sublicense Agreement expires or terminates with respect to a particular country, then the requirements set forth in Sections A and
B above, and Titan&#146;s or Aventis&#146; rights to the Venda IP, shall be limited to such country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Titan shall grant a license in the
Venda IP to Novartis as set forth in Section&nbsp;2.1 of the Sublicense Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. For purposes of the Venda Sublicense Agreement or
any approved sublicense thereunder, Subsection 8.5 of the Sublicense Agreement shall be deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 Except as other Wise expressly provided in this. Sublicense Agreement, under.ne circumstances shall a party hereto, as a
result of this Sublicense Agreement, obtain any ownership interest in or Other right to any technology, KNOW-HOW, patents pending patent applications, products, or biological material of the other party, or HMRI, including items owned, controlled,
discovered, invented or developed by the other party, or HMRI, or transferred by the other party or HMRI to said party, at any time pursuant to this Sublicense Agreement which is not a direct result of the study, KNOW-HOW and experimentation of
COMPOUND and PRODUCT. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="6%" VALIGN="top" ALIGN="left">****</TD> 
<TD ALIGN="left" VALIGN="top">C<SMALL>ERTAIN</SMALL> <SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL>
<SMALL>PORTIONS</SMALL>. </TD></TR></TABLE> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The last two paragraphs of Section&nbsp;17.1 of the Sublicense Agreement shall be deleted
in their entirety and replaced with the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="13%"></TD> 
<TD VALIGN="bottom" WIDTH="3%"></TD> 
<TD WIDTH="84%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With&nbsp;copies&nbsp;to;</P></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Titan Pharmaceuticals, Inc.</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Attention: ****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Telephone: ****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Facsimile: ****</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">and</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Telephone: ****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">Facsimile: ****</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Effectiveness</U>. This Amendment Agreement shall be deemed effective as of the date hereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. Miscellaneous. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a.
<U>Agreement Amended</U>. Subject to the provisions of this Section&nbsp;13, this Amendment Agreement shall be deemed to be an amendment to the Sublicense Agreement. All references to the Agreements in any other document, instrument, agreement or
writing hereafter shall be deemed to refer to the Agreements as amended hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Representation</U>. Titan represents as of the date
of this Amendment Agreement that Titan has received the prior written consent as required by Section&nbsp;12.1 (e)of the Sublicense Agreement to have the legal power, right and authority to enter into this Amendment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. <U>Successors and Assigns</U>. This Amendment Agreement shall be binding Upon and inure to the benefit of Titan and Novartis and their
respective successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. <U>Governing Law</U>. This Amendment Agreement shall be deemed tore been made in the State of New
York and its form, execution, validity, construction and effect shall be determined in accordance with the laws of the State of New York (without regard to New York&#146;s or any other jurisdictions conflict of laws principles). </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="6%" VALIGN="top" ALIGN="left">****</TD> 
<TD ALIGN="left" VALIGN="top">C<SMALL>ERTAIN</SMALL> <SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL>
<SMALL>PORTIONS</SMALL>. </TD></TR></TABLE> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the panics hereby have executed this Agreement by proper persons
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right"> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">

 
<TR> 
<TD WIDTH="9%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="90%"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><FONT STYLE="font-size:10pt">TITAN PHARMACEUTICALS, INC.</FONT></TD></TR>

 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sunil Bmonsel</P></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Sunil Bmonsel</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Exec. Vice President &amp; COO</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16" COLSPAN="3"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="3">NOVARTIS PHARMA AG</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Signatory Unknown</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hevre Girsault</P></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Hevre Girsault</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Head&nbsp;Global&nbsp;Partnering&nbsp;Business&nbsp;Development&nbsp;&amp;&nbsp;Licencsing</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr. Tom Chakraborti</P></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Dr. Tom Chakraborti</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">Senior Legal Counsel</TD></TR>
</TABLE></DIV> 
</BODY></HTML>
</TEXT>
</DOCUMENT>
